Sigma Life Science & Cofactor Genomics develop rat genome database
Publication date: 2 February 2011
Author: kdm communications limited
Tagged with: Cofactor Genomics, Edward Weinstein, Jon Armstrong, Sigma Life Science, Sigma-Aldrich
Sigma Life Science, the innovative biological products and services business of Sigma-Aldrich® (Nasdaq: SIAL), today announced that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat. As part of the agreement, Cofactor Genomics plans to generate and analyze sequence data using next generation sequencing systems, while SAGE Labs plans to provide the samples and to host a new, free public database at sageresearchmodels.com in late 2011. The database will include exclusive genomic information and analysis tools.
Currently, the Brown Norway is the only rat strain with a high quality draft sequence available. It was completed by the Rat Genome Consortium in 2004 with funding from the NIH. The draft sequence showed the rat shares nearly every gene implicated in human disease. However, since then, little work has been done, with the last update occurring in November of 2004.
The additional genome sequence provided by SAGE Labs and Cofactor Genomics should enable SAGE Labs to create improved models of human disease for the research community, while helping researchers to better pinpoint the crucial areas of biological difference between rats and humans. The creation of a new, public rat strain database could provide a quantum leap forward for better understanding the genetic basis of disease in humans.
Dr Edward Weinstein, Director of SAGE Labs at Sigma Life Science, said, “With the costs of whole genome sequencing rapidly coming down, it is now far more feasible to understand the genomes of the most widely used model organisms such as the rat. Sigma Life Science and its SAGE Labs initiative plan to lead the way in revealing these new genomes and making the information publically available.”
“This project and collaboration leverages Cofactor’s experimental design and analysis expertise to develop a global resource aimed at scientific discovery,” said Jon Armstrong, Chief Operating Officer of Cofactor Genomics.
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Fast plasma sample cleanup with new Phree Phospholipid Removal Plates (21 May 2012)
- Two overall winners announced at prestigious national award ceremony in London’s Science Museum (18 May 2012)
- New analysis of risk stratification for TYSABRI® published in New England Journal of Medicine (18 May 2012)
- NUCYNTA® ER (tapentadol) tablets provide pain management for patients with Diabetic Peripheral Neuropathy (DPN) (18 May 2012)
- GSK statement on tender offer to acquire Human Genome Sciences (18 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content